Short answer
Aardvark Therapeutics, Inc. (AARD) filed an 8-K current report with the SEC on August 17, 2026 reporting Item 5.07 (Submission of Matters to a Vote of Security Holders). 54.79% quorum, with 11,992,479 of 21,884,158 shares represented at the meeting.
Aardvark Therapeutics, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 5.07 · Submission of Matters to a Vote of Security Holders
- 54.79% quorum, with 11,992,479 of 21,884,158 shares represented at the meeting
- Victor Tong Jr. and Jeffrey Chi, Ph.D. elected Class I directors through the 2029 annual meeting
- BDO USA, P.C. auditor appointment ratified with 11,877,567 votes for and 24,018 against
- Stock-option repricing approved with 4,649,269 votes for versus 3,439,983 against, benefiting eligible participants
- Repricing approval may increase insider incentive alignment while creating potential shareholder dilution concerns
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Aardvark Therapeutics, Inc. 8-K filings
Get the next AARD 8-K as it lands
Follow AARD for push alerts, or ask the research agent what this filing means.